Total Current Assets Total Other Assets TOTAL ASSETS Total Current Liabilities Total Liabilities Total Stockholders’ Equity Balance Balance TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY Gross margin Total operating expenses Loss from operations Total other income (expense), net Loss before provision for income taxes Net loss Net loss Net income Balance (in Shares) Balance (in Shares) Equity Components [Axis] NET CASH (USED IN) / PROVIDED BY OPERATING ACTIVITIES NET CASH USED IN INVESTING ACTIVITIES NET CASH PROVIDED BY/(USED IN) FINANCING ACTIVITIES NET DECREASE IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS – BEGINNING OF PERIOD CASH AND CASH EQUIVALENTS – END OF PERIOD Organization and Nature of Business [Abstract] Summary of Significant Accounting Policies [Abstract] Schedule of Changes in the Allowance for Credit Losses [Abstract] Balance at beginning of year Balance at end of year Net of allowance for credit losses (in Dollars) Allowance for doubtful accounts Schedule of Revenue is Earned from Life Sciences Companies [Abstract] Statistical Measurement [Axis] Schedule of Weighted Average Shares Outstanding and the Basic and Diluted Earnings Per Common Share [Abstract] Acquisitions [Abstract] Schedule of Acquisition Date Fair Value of Consideration Transferred [Abstract] Fair value of consideration transferred Total Assets Acquired Total Liabilities Assumed Net assets acquired Fair value of consideration transferred Finite-Lived Intangible Assets by Major Class [Axis] Schedule of Revenue and Net Income of Medicx Health Included in the Company’s Consolidated Statement of Operations [Abstract] Business Acquisition [Axis] Schedule of Pro-Forma Consolidated Statement of Operations [Abstract] Investment Securities [Abstract] Prepaid Expenses [Abstract] Schedule of prepaid expenses [Abstract] Total prepaid expenses Property and Equipment [Abstract] Indefinite-Lived Intangible Assets [Axis] Goodwill and Intangible Assets [Abstract] Schedule of Goodwill on the Consolidated Balance Sheet [Abstract] Balance Balance Goodwill Schedule of Future Amortization Expenses of Intangibles Assets [Abstract] Total Deferred Revenue [Abstract] Schedule of Deferred Revenue [Abstract] Balance Balance Deferred revenue Related Party Transactions [Abstract] Stockholders' Equity [Abstract] Stock Based Compensation [Abstract] Schedule of Option Activity [Abstract] Outstanding at Number of Options Number of Options, Outstanding Outstanding at Number of Options Weighted average exercise price, Outstanding Outstanding at Aggregate intrinsic value Aggregate intrinsic value, Outstanding Exercise Price Range [Axis] Options, Nonvested at beginning balance Options, Nonvested at ending balance Weighted-Average Exercise Price, Nonvested at beginning balance Weighted-Average Exercise Price, Nonvested at ending balance Number of RSUs, beginning Number of RSUs Outstanding, ending Weighted average grant date fair value Outstanding, beginning Weighted average grant date fair value, Outstanding, ending Long-Term Debt [Abstract] Award Date [Axis] Extinguishment of Debt [Axis] Leases [Abstract] Total lease cost Schedule of Future Minimum Lease Payments [Abstract] Total Total lease liabilities Major Customers and Vendors [Abstract] Schedule of Customers Accounted Percentage of Revenue [Abstract] Customer [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Type [Axis] Income Taxes [Abstract] Schedule of Federal Income Tax [Abstract] Schedule of Net Deferred Tax [Abstract] Commitments and Contingent Liabilities [Abstract] Retirement Plan [Abstract] Subsequent Events [Abstract] Mr. William J. Febbo [Member] Ms. Marion Odence-Ford [Member] ASSETS Current Assets Cash and cash equivalents Short-term investments Accounts receivable, net of allowance for credit losses of $239,172 and $352,043 at December 31, 2023 and 2022, respectively Taxes receivable Prepaid expenses and other Property and equipment, net Other Assets Patent rights, net Technology assets, net Tradename and customer relationships, net Operating lease right-of-use assets Security deposits and other assets LIABILITIES AND STOCKHOLDERS’ EQUITY Current Liabilities Current portion of long-term debt Accounts payable – trade Accrued expenses Revenue share payable Current portion of lease liabilities Non-current Liabilities Long-term debt, net Lease liabilities, net of current portion Deferred tax liabilities, net Net deferred tax liabilities Commitments and contingencies (See Note 16) Stockholders’ Equity Preferred stock, $0.001 par value, 10,000,000 shares authorized, none issued and outstanding at December 31, 2023 and 2022, respectively Preferred stock, par value (in Dollars per share) Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, $0.001 par value, 166,666,667 shares authorized, 19,899,679 and 18,288,571 shares issued at December 31, 2023 and 2022, respectively Common stock, par value (in Dollars per share) Common stock, shares authorized Common stock, shares issued Treasury stock, par value (in Dollars per share) Treasury stock, purchased Additional paid-in-capital Accumulated deficit Net revenue Total Revenue Revenue Cost of revenues, exclusive of depreciation and amortization presented separately below Operating Expenses Stock-based compensation Impairment charges Asset impairment charges Impairments Depreciation and amortization Other sales, general and administrative expenses Other income (expense) Other income Interest income Weighted average number of shares outstanding – basic (in Shares) Basic EPS, Shares Weighted average number of shares outstanding – diluted (in Shares) Diluted EPS, Shares Loss per share – basic (in Dollars per share) Basic EPS, Per Share Amount Loss per share – diluted (in Dollars per share) Diluted EPS, Per Share Amount Stock-based compensation expense Options Restricted stock Issuance of common stock: For stock options exercised For stock options exercised (in Shares) Options exercised shares For acquisition For acquisition (in Shares) For restricted stock units vested, net of cancelled units For restricted stock units vested, net of cancelled units (in Shares) Repurchase of common stock (in Shares) Stock-based compensation expense Issuance of common stock: CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to reconcile net loss to net cash (used in) / provided by operating activities: Depreciation and amortization Increase in bad debt expense Bad debt expense Amortization of debt issuance costs Amortization of debt issuance costs (in Dollars) Change in operating assets and liabilities, net of the effects of acquisitions: Accounts payable Revenue share payable Accrued expenses and other liabilities Deferred revenue CASH FLOWS USED IN INVESTING ACTIVITIES: Proceeds from sale of property and equipment Proceeds from sale of business Redemptions of short-term investments CASH FLOWS (USED IN ) / PROVIDED BY FINANCING ACTIVITIES: Proceeds from long-term debt, net of issuance costs Proceeds from exercise of stock options, net of cash paid for withholding taxes SUPPLEMENTAL CASH FLOW INFORMATION: Cash paid for interest ROU assets obtained in exchange for lease obligations Reduction of EvinceMed purchase price for amounts previously paid Shares issued in connection with acquisition Cash paid for income taxes Treasury stock, $0.001 par value,1,741,397 and 1,214,398 purchased at December 31, 2023 and 2022, respectively Loss on disposal of a business